Abstract
Background
Immune editing, in which human leukocyte antigens (HLA) have critical roles, has been suggested to shape the landscape of human cancer. This study prospectively investigated whether HLA gene zygosity is associated with the prognosis of primary androgen deprivation therapy in advanced prostate cancer.
Methods
KYUCOG-1401-A was conducted in conjunction with a prospective clinical trial (KYUCOG-1401). Among the patients enrolled in KYUCOG-1401 and treated with primary androgen deprivation therapy, only Japanese patients were included. HLA genotypes of HLA-A, B, C, DRB1, DQB1, and DPB1 were determined. The effect of divergence of HLA genotypes on time to progression, prostate cancer-specific survival, and overall survival was evaluated.
Results
Among 127 patients, homozygosity for HLA-DRB1 (HR, 95% CI; 4.05, 1.54–10.7, P = 0.0047) and HLA-DQB1 (HR, 95% CI; 3.75, 1.47–9.58, P = 0.0058) was associated with an increased risk of prostate cancer-specific mortality. Patients with higher HLA evolutionary divergence scores at HLA-DQB1 (HR, 95% CI; 0.90, 0.82–0.97, P = 0.0093) had lower risks of prostate cancer-specific mortality. Androgen-responsive gene sets were upregulated in CD4low and CD8low tumors in the prostate cancer cohort, but not in the bladder and kidney cancer cohorts.
Conclusions
This study suggested that the diversity of HLA-II loci including HLA-DRB1 and HLA-DQB1 plays an important role in advanced prostate cancer survival, contributing to improved risk stratification in advanced prostate cancer. Moreover, it was shown that CD4+ T cells play an important role in androgen deprivation therapy, suggesting that immunotherapy targeting CD4+ T cells is promising for prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
Shiota M, Eto M. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol. 2016;23:360–9.
Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 2006;97:1190–3.
Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016;117:102–9.
Hemminki K, Ji J, Försti A, Sundquist J, Lenner P. Concordance of survival in family members with prostate cancer. J Clin Oncol. 2008;26:1705–9.
Cooperberg MR, Carroll PR, Dall’Era MA, Davies BJ, Davis JW, Eggener SE, et al. The state of the science on prostate cancer biomarkers: The San Francisco consensus statement. Eur Urol. 2019;76:268–72.
Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, et al. Predicting prostate cancer death with different pretreatment risk stratification tools: A head-to-head comparison in a nationwide cohort study. Eur Urol. 2020;77:180–8.
Ivanova M, Shivarov V. HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started. Int J Immunogenet. 2021;48:193–200.
Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, et al. MHC-I genotype restricts the oncogenic mutational landscape. Cell. 2017;171:1272–83.e15.
McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259–71.e11.
Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, et al. Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study. Endocr Relat Cancer. 2023;30:e230044.
Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.
Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59.
Kawai Y, Mimori T, Kojima K, Nariai N, Danjoh I, Saito R, et al. Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals. J Hum Genet. 2015;60:581–7.
Shiota M, Fujimoto N, Yamamoto Y, Takeuchi A, Tatsugami K, Uchiumi T, et al. Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guérin therapy for non-muscle invasive bladder cancer. Cancer Immunol Immunother. 2020;69:1155–63.
Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, et al. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. Cancer Immunol Immunother. 2023;72:1903–15.
Khor SS, Yang W, Kawashima M, Kamitsuji S, Zheng X, Nishida N, et al. High-accuracy imputation for HLA class I and II genes based on high-resolution SNP data of population-specific references. Pharmacogenomics J. 2015;15:530–7.
Pierini F, Lenz TL. Divergent Allele Advantage at Human MHC Genes: Signatures of Past and Ongoing Selection. Mol Biol Evol. 2018;35:2145–58.
Grantham R. Amino acid difference formula to help explain protein evolution. Science. 1974;185:862–4.
Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, et al. Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines. Cell Syst. 2018;6:271–81.e7.
Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173:291–304.e6.
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545–50.
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–73.
Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology. 1995;46:681–6.
Kitamura H, Torigoe T, Asanuma H, Honma I, Sato N, Tsukamoto T. Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition. J Urol. 2007;178:692–6.
Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother. 2010;59:529–40.
Chhibber A, Huang L, Zhang H, Xu J, Cristescu R, Liu X, et al. Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types. Immunity. 2022;55:56–4.e4.
Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, et al. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019;25:1715–20.
Blumenfeld W, Ye JQ, Dahiya R, Griffiss JM, Narayan P. HLA expression by benign and malignant prostatic epithelium: augmentation by interferon-gamma. J Urol. 1993;150:1289–92.
Younger AR, Amria S, Jeffrey WA, Mahdy AE, Goldstein OG, Norris JS, et al. HLA class II antigen presentation by prostate cancer cells. Prostate Cancer Prostatic Dis. 2008;11:334–41.
Zhao H, Zhang X, Shi Z, Guo B, Zhang W, He K, et al. Identification of a prognostic signature model with tumor microenvironment for predicting disease-free survival after radical prostatectomy. J Cancer. 2021;12:2371–84.
Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33:2376–83.
Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev. 2008;18:11–18.
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–34.
Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20:662–80.
Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019;574:696–701.
Parham P, Ohta T. Population biology of antigen presentation by MHC class I molecules. Science. 1996;272:67–74.
Ben-Batalla I, Vargas-Delgado ME, von Amsberg G, Janning M, Loges S. Influence of androgens on immunity to self and foreign: effects on immunity and cancer. Front Immunol. 2020;11:1184.
Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, et al. Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab. 2006;290:E856–63.
Gamat M, McNeel DG. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer. 2017;24:T297–T310.
Kissick HT, Sanda MG, Dunn LK, Pellegrini KL, On ST, Noel JK, et al. Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci USA. 2014;111:9887–92.
Doonan BP, Haque A. HLA class II antigen presentation in prostate cancer cells: A novel approach to prostate tumor immunotherapy. Open Cancer Immunol. 2010;3:1–7.
Acknowledgements
We would like to thank Ms. Noriko Hakoda and Ms. Eriko Gunshima for their technical assistance. We particularly thank Dr. Kaori Yasuda and Dr. Atsushi Doi (Cell Innovator, Fukuoka, Japan) for their excellent guidance in the HLA analysis. We also appreciate the Clinical Research Support Center Kyushu (CReS Kyushu) for their secretarial assistance and supportive assistance. We are grateful to the patients who volunteered to participate in this trial, as well as the following KYUCOG-1401-A investigators and trial staff: Noriaki Tokuda at Saga-ken Medical Centre Koseikan (Saga), Kentaro Kuroiwa at Miyazaki Prefectural Miyazaki Hospital (Miyazaki), Kazuya Kawahara at Kawahara Nephro-Urology Clinic (Aira), Motonobu Nakamura at National Hospital Organization Kyushu Cancer Center (Fukuoka), Ken Goto at Japanese Red Cross Fukuoka Hospital (Fukuoka), Sumitaka Mitsu at Kagoshima Prefectural Oshima (Amami), Masafumi Nagano at Fujimoto General Hospital (Miyakonojo), Naotaka Sakamoto at National Hospital Organization Kyushu Medical Center (Fukuoka), Youji Doman at Saiseikai Sendai Hospital (Satsumasendai), Hironobu Wakeda at Chiyoda Hospital (Hyuga), Yasufumi Nabekura at Kumamoto Urological Hospital (Kumamoto), Kohei Mizuma at National Hospital Organization Ibusuki Medical Center (Ibusuki), and Hisato Inatomi at Munakata Suikokai General Hospital (Fukutsu). Finally, we thank H. Nikki March, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.
Funding
This work was supported by a JSPS KAKENHI grant (17K11145), the Japanese Urological Association, Takeda Science Foundation, and Shinnihon Foundation of Advanced Medical Treatment Research to M.S. KYUCOG-1401 (UMIN000014243, jRCTs071180035) was supported by Astellas Pharma.
Author information
Authors and Affiliations
Contributions
Concept and design: MS and ME; Acquisition, analysis, or interpretation of data: MS and TT; Drafting of the manuscript: MS; Critical revision of the manuscript: All authors; Statistical analysis: MS; Obtaining funding: ME; Administrative, technical, or material support: All authors; Supervision: ME.
Corresponding author
Ethics declarations
Competing interests
MS received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, and Bayer and research funding support from Daiichi Sankyo. TK received research funding support from Janssen Pharmaceutical, Astellas Pharma, Shin Nippon Biomedical Laboratories, Ono Pharmaceutical, Bayer, Sanofi, and Takeda Pharmaceutical. HM received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Bayer, Chugai Pharmaceutical, and Merck and research funding support from Janssen Pharmaceutical, Takeda Pharmaceutical, and Kyowa Kirin. HS received honoraria from Takeda Pharmaceutical and Astellas Pharma. TI received honoraria from Janssen Pharmaceutical and Astellas Pharma. TK received honoraria from Takeda Pharmaceutical, AstraZeneca and Merck. AY received honoraria from Janssen Pharmaceutical and Astellas Pharma. ME received honoraria from Takeda Pharmaceutical, Janssen Pharmaceutical, AstraZeneca, and Astellas Pharma and research funding support from Astellas Pharma, Sanofi, and Takeda Pharmaceutical.
Ethics approval
The study protocol was approved by the institutional review board of each institute.
Consent to participate
All participants provided written informed consent.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Shiota, M., Tanegashima, T., Tatarano, S. et al. The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study. Prostate Cancer Prostatic Dis (2024). https://doi.org/10.1038/s41391-024-00808-0
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41391-024-00808-0